Google's Isomorphic Labs Eyes $2 Billion Plus Funding Round
Isomorphic Labs Inc., a subsidiary of Alphabet Inc. utilizing artificial intelligence to accelerate drug development, is allegedly negotiating to secure a new funding round.
The investment might be valued at over $2 billion. Thrive Capital, a backer of OpenAI Group PBC and a current investor in Isomorphic Labs, is anticipated to spearhead the round. Alphabet is said to contribute as well.
Isomorphic Labs was separated from the search giant's Google DeepMind machine learning research division in 2021. It is directed by Demis Hassabis, a co-founder of DeepMind. The executive and a fellow DeepMind employee together received half of the 2024 Nobel Prize in chemistry for their contributions to an AI model named AlphaFold 2. The algorithm can autonomously forecast protein structures, a job that traditionally took years of manual effort.
In 2024, Isomorphic Labs and DeepMind unveiled a greatly enhanced successor to the model. AlphaFold 3 provides over a 50percent improvement in accuracy for specific research tasks. It excels at examining small molecules, which are the biological components that serve as the foundation for numerous medications.
Also Read: 5 Key Leadership Appointments across Global Firms in March 2026
Isomorphic Labs’ main product is an AI system known as the Isomorphic Labs Drug Design Engine, or IsoDDE. Its purpose is to accelerate drug development initiatives by automating manual research processes. The Alphabet unit claims that IsoDDE can accomplish certain tasks much more effectively than Alpha Fold 3.
Investigators frequently initiate a drug development project by examining the proteins that constitute a disease-inducing cell. Specifically, they look for proteins that have what are known as binding pockets. These are access points through which medications can be introduced into the disease-causing cell to counteract it.
Isomorphic Labs assessed IsoDDE’s capability to identify binding pockets and execute associated tasks through a benchmark known as Runs N’ Poses. The company stated that the model surpassed AlphaFold 3's score by more than twofold in the most challenging tasks. One more advantage of IsoDDE is that it needs a relatively small amount of information about a protein to identify binding pockets. This decreases the extent of preliminary efforts required in pharmaceutical projects.
Also Read: How US–China Tariffs Are Disrupting Textile Trade
Once scientists pinpoint an appropriate binding site in a protein, they must discover a therapeutic molecule that can connect to it. IsoDDE accelerates that process too. It can forecast a compound's binding affinity, or its capacity to connect to a protein in a cell that causes disease, with much greater precision than previous techniques.
Also Read: US to Review AI Models from Microsoft, Google, xAI
Isomorphic Labs is said to intend to utilize the funding round it is securing to improve IsoDDE. The Alphabet division also intends to expand its global footprint.